Glycosylation type Ic disorder: idiopathic intracranial hypertension and retinal degeneration
- M Y Kahook1,
- N Mandava1,
- J B Bateman1,2,
- J A Thomas2
- 1Rocky Mountain Lions Eye Institute, Department of Ophthalmology, Denver, CO, USA
- 2Rocky Mountain Lions Eye Institute, Department of Pediatrics, Denver, CO, USA
- Correspondence to: Malik Y Kahook MD, 589 Franklin Blvd, Freedom, PA 15042, USA; malik.kahook{at}gmail.com
- Accepted 1 August 2005
We report a young woman with type Ic congenital disorder of glycosylation (CDG) with new clinical features of idiopathic intracranial hypertension, retinal degeneration, and novel mutations of ALG6. Patients with known or suspected CDG should receive a full ophthalmic examination including dilated fundus examination and electroretinography.
CDG is a rare group of autosomal recessive metabolic disorders. The two major subgroups are type I, caused by dysfunction of glycosylated protein assembly, and type II, caused by abnormal processing of glycosylated protein end products after assembly.1 Patients with type Ic (OMIM #603147) have mental retardation, axial hypotonia, very low factor XI, and seizures; the gene defect in α1,3-glucosyltransferase (human homologue of ALG6;OMIM *604566) encodes an enzyme that catalyses the transfer of the first glucose residue to the lipid linked oligosaccharide precursor for N-linked glycosylation. The reported ophthalmic manifestations of type I CDG are summarised in table I. We report a case of type Ic congenital disorder of …
